Authors' objectives: Surgical implantation of a bioprosthetic valve is the standard treatment for symptomatic severe aortic stenosis. Use of stented bioprostheses, which are designed to remain in position without the need for suturing, can reduce the length and invasiveness of surgery. We were requested by Mr. Gary Stoopler to review the evidence for one such valve, the ATS Enable Sutureless Bioprosthesis Model 6000.

Authors' recommendations: The evidence for the use of the 3f ATS Enable valve in aortic stenosis is provided by uncontrolled case series involving a relatively small number of published cases (~400 patients), with approximately 1 year follow-up. MUHC surgeons report that use of SuAVR facilitates partial sternotomy with associated reductions in operation time which may result in improved patient outcomes in selected cases. Optimal patient selection, side effect profile (particularly relative to the more established alternatives), and durability beyond ~1 year remain to be defined. From the perspective of the MUHC, use of SuAVR via mini-sternotomy instead of SAVR via standard sternotomy will have an increased budget impact of $3,750 per case. Offset savings may result in some increased efficiency.

Project Status: Completed

Year Published: 2013

URL for published report: http://www.mcgill.ca/tau/files/tau/muhc_tau_2013_71_suavr_a.pdf

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: Canada

Organisation Name: Technology Assessment Unit of the McGill University Health Centre (MUHC)

Contact Address: Technology Assessment Unit of the MUHC, Centre for Outcomes Research and Evaluation (CORE), Research Institute of the McGill University Health Centre, 5252 boul. de Maisonneuve, Bureau 3F.50, Montreal, Quebec H4A 3S5

Contact Name: nandini.dendukuri@mcgill.ca

Contact Email: nandini.dendukuri@mcgill.ca

Copyright: Technology Assessment Unit of the McGill University Health Centre (MUHC)